Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk sell-off is completely overdone, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk stock nearing two-year lows.
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food scientists warned of confusion and conflicts of interest.
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
On Monday, Novo Nordisk A/S NVO announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk: CagriSema Disappoints Again
Why Novo Nordisk Stock Is Falling Today
Shares of Novo Nordisk (NVO -8.70%) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m.
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk shares fall on weight loss drug trial results
Novo Nordisk (NYSE:NVO) shares moved lower after the Danish drugmaker unveiled the latest trial results for its weight loss drug CagriSema. The Phase 3 trial, called Redefine 2, showed that CagriSema helped obese or overweight adults with type 2 diabetes reduce their weight by 15.7% after 68 weeks, compared to 3.1% with placebo.
NVO Weight Loss Drug Disappoints, RDFN Acquisition, Airline Price Targets Slashed
Market weakness continued this morning, including in international companies like Novo Nordisk (NVO). Its next-gen weight loss drug trial results weren't enough to draw investors in.
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
Novo Nordisk's (NVO) U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their weight by 15.7% after 68 weeks. The stock dropped around 6.5% in Copenhagen, marking its biggest intraday decline since December 20.
